Innovative biotechnology company Leman Biotech, focused on cutting-edge cell therapy technology, has announced its official move to Zhongshan Life Science Park on November 21. This relocation marks a significant step forward in the development of a novel automated, fully enclosed CMC process for ultra-low dose CAR-T (chimeric antigen receptor T cell) products.
Meta10-19 CAR-T Therapy: Clinical Success with Ultra-Low Doses
Leman Biotech’s proprietary metabolic enhancement CD19 CAR-T therapy (Meta10-19 injection) has demonstrated remarkable results in investigator-initiated clinical trials (IIT). With an ultra-low dosage, as low as 1% of traditional CAR-T therapy doses, the treatment has achieved complete tumor cell clearance, helping over 20 patients with relapsed/refractory leukemia or lymphoma to reach complete remission (CR) and be discharged. In the second half of 2024, the therapy achieved further clinical progress, with the injection dose of metabolic enhancement CAR-T cells further reduced to one-thousandth (1‰) of the conventional dose, again successfully aiding multiple patients in achieving complete remission.
Advantages of Ultra-Low Dose for Automation
The ultra-low dosage required for metabolic enhancement CD19 CAR-T cells creates favorable conditions for the development of automated production processes. Leman Biotech has assembled a dedicated team to develop a new automated CAR-T cell preparation process. With the comprehensive R&D facilities and full-range scientific support services in Zhongshan Life Science Park, the company aims to accelerate the progress and production implementation of this R&D project. By combining ultra-low doses with a new automated production process, Leman Biotech expects to reduce the production cycle from nearly one month to approximately one week, compared to traditional CAR-T cell preparation.
Future Integration of Meta10, AI, and Automation
Looking ahead, Leman Biotech will leverage the strong scientific research capabilities of the Chinese Academy of Sciences’ Institute of Medicinal Plant Development and collaborate with advanced technology partners like Jingtai Technology to efficiently integrate its core technologies—Meta10, artificial intelligence (AI), and new automated production techniques (Auto)—to drive revolutionary progress in CAR-T therapy. This integrated strategy aims to significantly reduce the production costs and enhance the efficiency of CAR-T cell therapy, making this cutting-edge treatment more accessible and affordable for patients in need.-Fineline Info & Tech
Leave a Reply